Trials / Conditions / Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma

Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma

10 registered clinical trials studyying Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Active Not Recruiting	Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have R NCT05627245	National Cancer Institute (NCI)	Phase 1
Recruiting	Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cel NCT04848064	John Reneau	Phase 1
Completed	Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas NCT04774068	Walter Hanel	Phase 1
Withdrawn	Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell Lymphomas NCT03373305	City of Hope Medical Center	Phase 1
Terminated	Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory No NCT03432741	Mayo Clinic	Phase 1
Completed	Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymp NCT03409432	John Reneau	Phase 2
Active Not Recruiting	Study of Pembrolizumab (MK-3475) in Combination With Romidepsin NCT03278782	M.D. Anderson Cancer Center	Phase 1 / Phase 2
Active Not Recruiting	Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractor NCT02978625	National Cancer Institute (NCI)	Phase 2
Recruiting	A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemi NCT03017820	Mayo Clinic	Phase 1
Completed	Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfun NCT01638533	National Cancer Institute (NCI)	Phase 1